BioSpace News Archive

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2021 results on Wednesday, February 23, 2022 at 1 p.m. London time (8 a.m. Eastern Time).

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published an update regarding the regulatory progress of RGN-259 on the Company’s website at www.regenerx.com.

Elpis Biopharmaceuticals, a clinical stage biopharmaceutical company developing next generation multifunctional immunotherapies to transform cancer treatment, today announced the appointment of Vincenzo Bronte, M.D., of the University of Verona in Italy, to its Scientific Advisory Board.

Anavasi Diagnostics, a medical technology company focused on the development of novel molecular diagnostic testing, recently announced the addition of a Chief Financial Officer, Chief Operating Officer and Chief Commercial Officer to its management roster.

The first East Coast installation of the MOMENTUM Magnetic Particle Imaging (MPI) scanner has been completed at Kennedy Krieger Institute in Baltimore, MD.

Health Canada completed a safety review that confirmed a link between the use of Xeljanz/Xeljanz XR and the increased risks of serious heart-related problems and cancer, especially in older patients, patients who are current or past smokers, and patients with cardiovascular or cancer risk factors.

Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2022, ended December 31, 2021, after the market close on Wednesday, January 26, 2022.

On January 10, 2022, the tri-agencies, Department of Labor (DOL), Health and Human Services (HHS) and Treasury issued new guidance that supports women’s access to U.S. Food and Drug Administration (FDA) approved contraceptive products.

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a new patent (No. 11,219,684) for the method of preparing COVID-19 peptide specific cytotoxic T cells (CTLs) for the treatment of COVID-19 infection.

Samsung Biologics (KRX: 207940.KS) announced its sustainable growth plan for this year at the 2022 Annual JP Morgan Healthcare Conference.